ReproCell Aktsia

ReproCell P/FCF

P/FCF (hinna ja vaba rahavoo suhe) ettevõttest ReproCell (4978.T) seisuga 14. aug 2026 on −192,13. Eelmisel aastal oli P/FCF (hinna ja vaba rahavoo suhe) −84,46 — muutus 127,47% (madalam).

P/FCF

−192,13

YoY

127,47%

Viimati uuendatud:

P/FCF (hinna ja vaba rahavoo suhe) ettevõttest ReproCell on 2026 −192,13 . P/FCF (hinna ja vaba rahavoo suhe) ettevõttest ReproCell oli 2025 −84,46 . See väheneb 127,47% madalam võrreldes eelmise aastaga.
Access this data via the Eulerpool API

ReproCell Aktsiate analüüs

Mida ReproCell teeb? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell on üks populaarsemaid ettevõtteid Eulpoolist.

Sageli esitatud küsimused ReproCell aktsia kohta

ReproCell P/FCF (hinna ja vaba rahavoo suhe) on 2026. aastal −192,13.

P/FCF (hinna ja vaba rahavoo suhe) ettevõttest ReproCell muutus −84,46 -st −192,13 -ks, mis vastab 127,47% muutusele. Väärtus on madalam kui eelmisel aastal.

Eulpoolist leiate P/FCF (hinna ja vaba rahavoo suhe) ReproCell täieliku ajaloolise arengu alates 2006. aastast – koos aastate väärtustega, graafikutega ja üksikasjalike analüüsidega.

Hinna ja vaba rahavoo suhe mõõdab, kui palju peavad investorid maksma iga vaba rahavoo ühiku eest. Madalam suhe võib näidata paremat väärtust.

P/FCF = turukapitalisatsioon / vaba rahavoog

P/FCF (hinna ja vaba rahavoo suhe) hindamiseks on oluline võrrelda seda sama tööstuse ja sektori ettevõtetega. Eulpoolis leiate P/FCF (hinna ja vaba rahavoo suhe) jaoks otsesed tööstusesisesed võrdlused.

Hea väärtus varieerub tööstuse ja ettevõtte arenguetapi järgi. Eulpoolis saate P/FCF (hinna ja vaba rahavoo suhe) ReproCell võrrelda sektori konkurentidega ja tööstuse keskmisega, et hinnata selle atraktiivsust.

Access this data via the Eulerpool API

Hindamine — ReproCell

Kõik finantsnäitajad — ReproCell